This project forms the basis of a Clinical Associate Physician grant for Linda Anne DiMeglio, MD. It will be used as a supplement for the General Clinical Research Center (GCRC) at the Indiana University School of Medicine. The broad objective is to provide a five-year period of mentored support for Dr. DiMeglio to facilitate her development as an independent clinical investigator. The application includes both a systematic career development plan and a clinical research project. The career development plan includes: l) completion of the Indiana University GCRC Department of Medicine two year Clinical Investigator Training Enhancement Program, 2) completion of a Master's Degree Ln Public Health, and 3) careful mentorship by Munro Peacock, MD, Ora Pescovitz, MD, and other researcher physicians to foster Dr. DiMeglio's evolution into a productive and independent clinical research investigator. The clinical research proposal describes a study to evaluate the efficacy and safety of """"""""Bisphosphonate Therapy for Osteogenesis Imperfecta (OI)."""""""" OI is a heritable disorder of collagen synthesis. Affected persons have low bone mineral density and experience multiple fractures and progressive bony deformity. In its most severe form, the disorder is lethal in infancy. To date, no effective therapy exists for this debilitating condition. Improyements in bone mineral density and in fracture rates in a small number of children treated with intravenous bisphosphonates have been reported. The efficacy of oral bisphosphonates has not been established. We will characterize the changes effected by oral bisphosphonate therapy and compare them to a regimen of intravenous bisphosphonate therapy in a group of children with OI.
|DiMeglio, Linda A; Peacock, Munro (2006) Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta. J Bone Miner Res 21:132-40|
|Dimeglio, L A; Ford, L; McClintock, C et al. (2005) A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta. J Pediatr Endocrinol Metab 18:43-53|
|Segal, David G; Pescovitz, Ora Hirsch; Schaefer, G Bradley et al. (2004) Craniofacial and acral growth responses in growth hormone-deficient children treated with growth hormone. J Pediatr 144:437-43|
|DiMeglio, L A; Ford, L; McClintock, C et al. (2004) Intravenous pamidronate treatment of children under 36 months of age with osteogenesis imperfecta. Bone 35:1038-45|
|DiMeglio, Linda A; Boyd, Sheryl R; Pottorff, Tina M et al. (2004) Preschoolers are not miniature adolescents: a comparison of insulin pump doses in two groups of children with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 17:865-70|